364 related articles for article (PubMed ID: 12653923)
1. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.
Galadari H; Fuchs B; Lebwohl M
Int J Dermatol; 2003 Mar; 42(3):231-7. PubMed ID: 12653923
[TBL] [Abstract][Full Text] [Related]
2. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
3. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
4. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
[TBL] [Abstract][Full Text] [Related]
5. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
Hamilton TK
J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
[TBL] [Abstract][Full Text] [Related]
6. Cytokine blockers in psoriatic arthritis.
Mease PJ
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii37-40. PubMed ID: 11890650
[TBL] [Abstract][Full Text] [Related]
7. [Biological agents in treatment of psoriatic arthritis].
Lewicki M; Dutkiewicz B; Widuchowska M; Kucharz EJ
Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
[TBL] [Abstract][Full Text] [Related]
8. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
9. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
10. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.
Woolacott NF; Khadjesari ZC; Bruce IN; Riemsma RP
Clin Exp Rheumatol; 2006; 24(5):587-93. PubMed ID: 17181932
[TBL] [Abstract][Full Text] [Related]
11. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin.
Braun J; Sieper J
BioDrugs; 2003; 17(3):187-99. PubMed ID: 12749755
[TBL] [Abstract][Full Text] [Related]
12. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
Saad AA; Symmons DP; Noyce PR; Ashcroft DM
J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
14. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.
Wong VK; Lebwohl MG
Expert Opin Biol Ther; 2005 Nov; 5(11):1505-13. PubMed ID: 16255653
[TBL] [Abstract][Full Text] [Related]
15. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-alpha agents in the treatment of psoriatic arthritis.
Brandt J; Braun J
Expert Opin Biol Ther; 2006 Feb; 6(2):99-107. PubMed ID: 16436036
[TBL] [Abstract][Full Text] [Related]
17. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
[TBL] [Abstract][Full Text] [Related]
18. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
Haberhauer G; Strehblow C; Fasching P
Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
[TBL] [Abstract][Full Text] [Related]
19. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]